Press Releases

06.17.2019

Pfizer to Acquire Array BioPharma

06.12.2019

Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor

06.05.2019

Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development

05.24.2019

Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures

05.15.2019

Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting

05.15.2019

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

05.14.2019

FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma

05.09.2019

Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts

05.08.2019

Pfizer Acquires Clinical-Stage Biotech Therachon

05.07.2019

European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

05.06.2019

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

04.30.2019

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS